Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Itepekimab in Adult Japanese Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
NCT07484230Phase 3Withdrawn
- Sponsor
- Sanofi
- Start
- May 2026
- Primary completion
- Oct 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of itepekimab in chronic rhinosinusitis with nasal polyps (CRSwNP), sponsored by Sanofi. Planned start May 2026; status: withdrawn.
02
Drugs
itepekimab
03
Conditions
chronic rhinosinusitis with nasal polyps (CRSwNP)
Beyond the preview
Go deeper on NCT07484230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07484230.